Volume 10, Issue 1 (7-2012)                   IJRM 2012, 10(1): 41-46 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ramazanzadeh F, Tavakolianfar T, Shariat M, Purafzali Firuzabadi S J, Hagholahi F. Levonorgestrel-releasing IUD versus copper IUD in control of dysmenorrhea, satisfaction and quality of life in women using IUD. IJRM 2012; 10 (1) :41-46
URL: http://ijrm.ir/article-1-253-en.html
Levonorgestrel-releasing IUD versus copper IUD in control of dysmenorrhea, satisfaction and quality of life in women using IUD
Fatemeh Ramazanzadeh1 , Toktam Tavakolianfar * 2, Mamak Shariat3 , Seyed Javad Purafzali Firuzabadi4 , Fedieh Hagholahi1
1- Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Midwifery, Tarbiat Modaress University, Tehran, Iran , tavakolianfar@iau-neyshabur.ac.ir
3- Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran
4- Student Research Assembly, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract:   (2626 Views)
Background: The levonorgestrel-releasing IUD can help the treatment of dysmenorrhea by reducing the synthesis of endometrial prostaglandins as a conventional treatment.
Objective: This study was performed to assess the frequency of dysmenorrhea, satisfaction and quality of life in women using Mirena IUDs as compared to those using copper IUDs.
Materials and Methods: This double-blind randomized clinical trial was performed between 2006 and 2007 on 160 women aged between 20 to 35 years who attended Shahid Ayat Health Center of Tehran, and they were clients using IUDs for contraception. 80 individuals in group A received Mirena IUD and 80 individuals in group B received copper (380-A) IUD. Demographic data, assessment of dysmenorrhea, and follow-up 1, 3 and 6 months after IUD replacement were recorded in questionnaires designed for this purpose. To assess the quality of life, SF36 questionnaire was answered by the attending groups, and to assess satisfaction, a test with 3 questions was answered by clients.
Results: Dysmenorrhea significantly was decreased in both groups six months after IUD insertion as compared to the first month (p<0.001). However, statistically, Mirena reduced dysmenorrhea faster and earlier compared to cupper IUD (p<0.003). There isn’t any significant difference between these two groups in satisfaction and quality of life outcomes.
Conclusion: There is no difference between these two groups in terms of the satisfaction and quality of life, therefor the usage of Mirena IUD is not a preferred contraception method.
Keywords: Dysmenorrhea, Intrauterine devices, Copper, Levonorgestrel-releasing IUD, Patient satisfaction.
Full-Text [PDF 518 kb]   (508 Downloads) |   |   Full-Text (HTML)  (473 Views)  
Type of Study: Original Article |
References
1. Cunningham FG, Leveno KJ. Williams Obestetrics 20th edition. New York: McGraw-Hill. Medical publishing devision; 2010: 686.
2. Morrow C, Naumburg EH. Dysmenorrhea. Prim Care 2009; 36: 19-32. [DOI:10.1016/j.pop.2008.10.004]
3. Howard FM, Perry CP, Carer JE, et al. Pelvic Pain Diagnosis and Treatment. Philadelphia: Lippincott Williams and Wilkins; 2000: 100-180.
4. Jiménez MF, Arbo E, Vetori D, de Freitas FM, Cunha-Filho JS. The effect of the Levonorgestrel-releasing intrauterine system and copper intrauterine device on subendometrial microvascularization and uterine artery blood flow. Fertil Steril 2008; 90: 1574-1578. [DOI:10.1016/j.fertnstert.2007.10.004]
5. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005; 9: CD002126. [DOI:10.1002/14651858.CD002126.pub2]
6. Fedele L, Bianchi S, Zanconato G, Portuese A. Raffaellio use of a levonorgestrel- releasing intrauterine device in the treatment of rectovaginal endometriosis Fertil Steril 2001; 75: 485-488. [DOI:10.1016/S0015-0282(00)01759-3]
7. Thonneau P, Almont T. Contraceptive efficacy of intrauterine devices. Am J Obstet Gynecol 2008; 198: 248-253. [DOI:10.1016/j.ajog.2007.10.787]
8. Gupta H, Singh V. Levonorgestrel intrauterine system: a revolutionary intra-uterine device. Contraception 2007; 105: 380-382.
9. Montazeri A, Gashtasbi A, Vahdaninya M. Translate and determine the validity and reliability of such questionnaires Persian SF36. Payesh J 2005; 5: 49-56.
10. Lumsden MA, Kelly RW, Baird DT. Primary dysmenorrhea: the importance of both prostaglandins E2 and F2α. Br J Obstet Gynecol 1938; 90: 1135-1140. [DOI:10.1111/j.1471-0528.1983.tb06460.x]
11. Strömberg P, Äkerlund M, Forsling ML, Kindahl H. Involvement of prostaglandins in vasopressin stimulation of the human uterus. Br J Obstet Gynecol 1983; 93: 332-337. [DOI:10.1111/j.1471-0528.1983.tb08919.x]
12. Wildemeersch D, Schacht E. Treatment of menorrhagia with a novel "frameless" intrauterine levonorgestrel- releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care 2001; 6: 93-101. [DOI:10.1080/ejc.6.2.93.101]
13. Wildemeersch D, Schacht E. Endometrial suppression with a new "frameless" levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study. Maturitas 2000; 36: 63-68. [DOI:10.1016/S0378-5122(00)00136-5]
14. Wildemeersch D, Schacht E. Contraception with a novel "frameless" intrauterine levonorgestrel- releasing drug delivery system: A pilot study. Eur J Contracept Reprod Health Care 2000; 5: 234-240. [DOI:10.1080/13625180008500399]
15. Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009; 79: 189-193. [DOI:10.1016/j.contraception.2008.11.004]
16. Regine S, Pirjo I. The levonorgestrel intrauterine system: long term contraception and therapeutic effect. Future Medicine 2005; 1: 171-172.
17. Gupta HP, Singh U, Sinha S. Levonorgestrel intra-uterine system- a revolutionary intra- uterine device. J Indian Med Assoc 2007; 105: 382-385.
18. Bahamondes L, Bahamondes MV, Monteiro I. Levonorgestrel-releasing intrauterine system: uses and controversies. Expert Rev Med Devices 2008; 5: 437-445. [DOI:10.1586/17434440.5.4.437]
19. Kriplani A, Singh BM, Lal S, Agarwal N. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet 2007; 97: 190-194. [DOI:10.1016/j.ijgo.2007.01.009]
20. ESHRE Capri Workshop Group. Intrauterine devices and intrauterine systems. Hum Reprod Update 2008; 14: 197-208. [DOI:10.1093/humupd/dmn003]
21. Mansour D. Avoiding sterilization with the Levonorgestrel- releasing intrauterine system (Mirena®). Gynaecology Forum 2008; 13: 9-14.
22. Jiménez MF, Vetori D, Fagundes PA, de Freitas FM, Cunha-Filho JS. Subendometrial microvascularization and uterine artery blood flow in IUD- induced side effects (levonorgestrel intrauterine system and copper intrauterine device. Contraception 2008; 78: 324-327. [DOI:10.1016/j.contraception.2008.06.013]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb